Yefei Xiao
Overview
Explore the profile of Yefei Xiao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cao B, Xiao Y, Liu D
Transl Psychiatry
. 2024 Jul;
14(1):297.
PMID: 39030164
Methylmalonic acid (MMA), a biomarker of mitochondrial dysfunction, has been reported to be associated with depression in specific populations (i.e., older adults and postpartum women). Our study aimed to investigate...
2.
Zhang C, Li S, Shen L, Teng X, Xiao Y, Yang W, et al.
Cancer Immunol Immunother
. 2024 May;
73(7):123.
PMID: 38727812
Adoptively transferred T cell receptor-engineered T cells are a promising cancer treatment strategy, and the identification of tumour-specific TCRs is essential. Previous studies reported that tumour-reactive T cells and TCRs...
3.
Cao B, Shao X, Xiao Y, McIntyre R, Teopiz K, Li R, et al.
Obes Rev
. 2023 Oct;
25(1):e13645.
PMID: 37814428
The prevalence of depression and obesity in the pediatric population has increased along with multiple adverse health outcomes in later life. However, the mechanisms underlying the bidirectional relationship between obesity...
4.
Zhang C, Sun Y, Li S, Shen L, Teng X, Xiao Y, et al.
J Immunother Cancer
. 2022 Oct;
10(10).
PMID: 36307150
Background: Although adoptive cell therapy with tumor infiltrating lymphocytes (TILs) has mediated effective antitumor responses in several cancers, dysfunction and exhaustion of TILs significantly impair the therapeutic effect of TILs....
5.
Zhang C, Sun Y, Li S, Shen L, Teng X, Xiao Y, et al.
Clin Transl Immunology
. 2022 Oct;
11(9):e1419.
PMID: 36188121
Objectives: Although adoptive cell therapy with T-cell receptor-engineered T cells (TCR-Ts) has mediated effective antitumor responses in several cancers, senescence of T cells could impair the therapeutic effect of TCR-Ts....
6.
Li S, Zhang C, Shen L, Teng X, Xiao Y, Yu B, et al.
Cancer Immunol Immunother
. 2022 Aug;
72(3):769-774.
PMID: 35988132
NK cells, especially FDA-approved NK-92 cells, could be used for TCR engineering owing to their specialized cytotoxicity against tumors, safety profile and potential use as an off-the-shelf cellular therapy. The...
7.
Shen L, Xiao Y, Zhang C, Li S, Teng X, Cui L, et al.
Cancer Lett
. 2022 Apr;
538:215710.
PMID: 35489446
The inadequate in vivo persistence of chimeric antigen receptor (CAR)-modified T cells has been shown to lead to poor therapeutic efficacy and disease recurrence. In vivo persistence is associated with...
8.
Shen L, Xiao Y, Tian J, Lu Z
Cancer Lett
. 2022 Jan;
529:139-152.
PMID: 35007698
The dramatic success of adoptive transfer of engineered T cells expressing chimeric antigen receptor (CAR-T) has been achieved with effective responses in some relapsed or refractory hematologic malignancies, which is...